The FDA issued recommendations for a BLA submission regarding a global Phase 3 study conducted by Larimar Therapeutics, utilizing the START pilot program.

The entities involved

• FDA →
  • Amidst panel votes, Robert F. Kennedy Jr. seeks to overturn FDA restrictions regarding peptides, while critics question safety data.06:03
  • Replimune Group, Inc. received accelerated approval for TUDRIQEV™ in advanced melanoma, while its stock price reflected quarterly EPS misses.05:01
• Start →

  Nothing else this week.

• Europe →

  terrestrial continent located in north-western Eurasia

  • Mickey Heller served as a navigator in Bomber Command in Europe and was in the Royal Canadian Air Force.07:30
  • Russia pressures Finland on territorial claims, Musk restricts Starlink service to Ukraine, and Kherson conflict drives European aid efforts.07:07
• U.K. →
  • The rock tours industry is expanding its market reach, with tours heading to Europe, the U.K., North America, Asia, and Australia.Wed 23:21
  • Trump DOJ moves to sideline citizens, EPA weakens pollution rules, and the UK approves a new gas project.Wed 21:42

Related events

• Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.Jul 1
• BMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.Jun 22
• Helus Pharma is seeking review from the FDA for its drug candidate HLP003, led by company executive Eric So.Jun 26